Arrowhead Pharmaceuticals Inc. (ARWR)
Summary
ARWR Chart
Arrowhead: Stock Up On SHTG Data - No Ceiling On Valuation Growth Potential
Arrowhead Pharmaceuticals surged nearly 20% after strong Phase 3 results for plozasiran in severe hypertriglyceridemia, showing 79–81% triglyceride reductions and significant acute pancreatitis risk reduction. Plozasiran's quarterly dosing, robust efficacy, and favorable safety profile position ARWR to challenge Ionis's Tryngolza in the lucrative sHTG market, with regulatory filings planned before year-end. ARWR's TRIM platform is attracting major partnerships and milestone payments, with a pipeline spanning obesity, cardiovascular, and metabolic diseases, supporting long-term revenue growth potential.
Arrowhead Pharmaceuticals: Redemplo Meets High Expectations In SHTG Trials
Arrowhead Pharmaceuticals reported positive phase 3 results for Redemplo, achieving 79-81% triglyceride reductions and significant acute pancreatitis risk reduction in severe hypertriglyceridemia. Redemplo demonstrates strong efficacy, quarterly dosing, and a favorable safety profile versus Ionis' Tryngolza, positioning ARWR for leadership in the SHTG market. Tryngolza has a first-mover advantage and administration with an autoinjector versus the current prefilled syringe for Redemplo, but ARWR expects to have an autoinjector as well.
These major drug stocks rally after Trump's zero tariff announcement
President Donald Trump has announced that all generic drugs imported into the United States would continue to enjoy a zero-percent tariff for another two years, sending major drug stocks up.
Arrowhead Pharmaceuticals Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 354 | $6,005.56 | $25,714.56 | $19,709 | 328.18% |
| ML Marc Larkins Johnson & Johnson | 247,598 | $15.46M | $17.99M | $2.53M | 16.35% |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 100 | $6,639 | $7,264 | $625 | 9.41% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 511 | $26,757.52 | $37,098.6 | $10,341.08 | 38.65% |
 Farallon Capital Farallon Capital Management LLC | 15,800 | $297,040 | $1.15M | $852,100.32 | 286.86% |
Arrowhead Pharmaceuticals Inc. (ARWR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Arrowhead Pharmaceuticals Inc. ever had a stock split?
Arrowhead Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Christopher R. Anzalone CEO | NASDAQ (NGS) Exchange | 04280A100 CUSIP |
| US Country | 711 Employees | - Last Dividend | 17 Nov 2011 Last Split | 16 Jun 1993 IPO Date |
Overview
Arrowhead Pharmaceuticals, Inc. is a pioneering company focused on the development of innovative medicines for the treatment of intractable diseases. With a comprehensive pipeline of products undergoing various stages of clinical trials, the company is at the forefront of addressing challenging health conditions that impact populations in the United States. Arrowhead is dedicated to finding novel therapeutic solutions for patients with a range of diseases, leveraging cutting-edge research and strategic collaborations. Established in 2003 and based in Pasadena, California, the organization has formed key partnerships with industry leaders to advance its mission of bringing groundbreaking treatments to market.
Products and Services
Arrowhead Pharmaceuticals, Inc.'s robust pipeline encompasses a variety of products, each targeting specific intractable diseases through different stages of clinical development:
- Plozasiran - Currently in Phase 2b and one Phase 3 clinical trial, Plozasiran aims to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome, offering potential relief for patients with these lipid disorders.
- Zodasiran - In Phase 2b clinical trials, Zodasiran is being evaluated for its capability to treat dyslipidemia and hypertriglyceridemia, further highlighting Arrowhead’s commitment to addressing cardiovascular diseases.
- ARO-PNPLA3 - This candidate is in a Phase 1 clinical trial targeting non-alcoholic steatohepatitis (NASH), a liver condition that currently lacks sufficient therapeutic options.
- ARO-RAGE - Undergoing Phase 1/2a clinical trials, ARO-RAGE is developed for treating inflammatory pulmonary conditions, indicating Arrowhead’s foray into respiratory diseases.
- ARO-MUC5AC - This product is in Phase 1/2a clinical trials for the treatment of muco-obstructive pulmonary diseases, aiming to address unmet needs in pulmonary care.
- ARO-MMP7 - In Phase 1/2a clinical trials, ARO-MMP7 is targeted for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease.
- ARO-DUX4 - For patients with facioscapulohumeral muscular dystrophy, ARO-DUX4 represents a hopeful treatment currently in development.
- ARO-SOD1 - Arrowhead is exploring the potential treatment of amyotrophic lateral sclerosis (ALS) with ARO-SOD1.
- ARO-C3 - In Phase 1/2a clinical trial, ARO-C3 targets various complement mediated or associated renal diseases, extending its efforts to renal health.
- JNJ-3989 - Partnered with Janssen Pharmaceuticals, Inc., this product in Phase 2 clinical trial aims to treat chronic hepatitis B virus infection.
- Olpasiran - This candidate is in a crucial Phase 3 clinical trial to reduce the production of apolipoprotein A, a factor in cardiovascular disease.
- GSK-4532990 - In collaboration with GlaxoSmithKline, this Phase 2 clinical trial candidate seeks to address liver diseases, showing the breadth of Arrowhead's therapeutic aims.
- HZN-457 - Developed in partnership with Horizon Therapeutics Ireland DAC, HZN-457 is currently in phase 1 clinical trial targeting uncontrolled gout.
- Fazirsiran - In a Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency, Fazirsiran signifies Arrowhead's commitment to liver health.
Moreover, Arrowhead Pharmaceuticals has entered into strategic license and research collaboration agreements with notable entities including Janssen Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Horizon Therapeutics Ireland DAC, Amgen Inc., and GlaxoSmithKline Intellectual Property (No. 3) Limited, underscoring its collaborative and innovative approach to drug development.
